Venture capital deployed · 2026 YTD
Sector market cap
Largest raise · trailing 12mo
Catalysts ahead · next 12mo
Companies tracked
Nothing on the calendar yet.
Mega-rounds dominate the past year. Precision Neuroscience raised $250M in September 2026, Merge Labs $252M in January, BrainCo $286M in January, and Science Corporation $230M in March. Seed and Series A rounds stay near $10M to $55M, so the spread between top and typical deals has widened sharply.
Capital is concentrating in late-stage and strategic deals. Of the roughly $1.5B raised since January 2026, most went to Series C and above, strategic, or seed-stage Merge Labs, which is an outlier at $252M. Early-stage rounds such as Subsense's $10M seed and NextSense's $16M Series A remain small and scarce.
OpenAI led Merge Labs' $252M seed at an $850M valuation, and Khosla Ventures appears on Science Corporation's $230M Series C after leading its earlier Series B rounds. Alibaba led StairMed's $73M strategic round. Golden Falcon Capital has backed Subsense twice. Longtime backer Khosla has gone quiet since 2025, and ARCH Venture Partners has no rounds on file after 2022.
BCI's real bottleneck isn't surgical implants—it's decoding speed, and pooled training data is cracking it open.
The BCI sector is fracturing between invasive and non-invasive camps—and capital is chasing the wrong one.
BCI’s next regulatory moat isn’t safety—it’s proving its implants can outlast the brain’s own immune system.
BCI’s real battle isn’t hardware—it’s the race to own the neural dataset that trains the next AI.
As of 2026-08-01